Skip to Content

Zinbryta Approval History

  • FDA approved: Yes (First approved May 27th, 2016)
  • Brand name: Zinbryta
  • Generic name: daclizumab
  • Dosage form: Injection
  • Company: Biogen
  • Treatment for: Multiple Sclerosis

Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Development History and FDA Approval Process for Zinbryta

DateArticle
Mar  2, 2018Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for Zinbryta (daclizumab) for Relapsing Multiple Sclerosis
May 28, 2016Approval FDA Approves Zinbryta (daclizumab) to Treat Multiple Sclerosis
Apr 29, 2015FDA Accepts BLA for Zinbryta (Daclizumab High-Yield Process) for Treatment of MS
Aug  9, 2011Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis
Feb 16, 2010Daclizumab Shows Potential For New Immunoregulatory Approach To Treating Multiple Sclerosis, According To Data Published In The Lancet Neurology
Oct 12, 2007Phase 2 Data Show Daclizumab Significantly Reduced MultipleSclerosis Lesions in Patients Receiving Interferon Beta Therapy
Mar 12, 2007Primary Endpoint Met in Phase 2 Trial of Daclizumab in PatientsWith Relapsing Multiple Sclerosis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide